Cód. SSPA: IBiS-C-01
Our laboratory is a multidisciplinary and translational group whose main lines of research are:
Research Lines:
- Molecular biology of cancer
We study the molecular and cellular mechanisms of cancer, using in vitro and in vivo models and patient samples. We focus on:
- Identification of new alterations that induce cell dedifferentiation and/or reprogramming.
- Study of deep molecular alterations that generate the dedifferentiation of cancer cells into tumor stem cells, understanding how these alterations cause an increase in resistance to therapy, local recurrence and metastasis.
- Identification and characterization of molecular alterations that prevent senescence and induce immortalization in mammalian cells.
- Identification of new therapeutic targets for antitumor treatment. Identification of prognostic or predictive biomarkers in cancer.
Contact: Amancio Carnero (acarnero-ibis@us.es)
- Mechanisms of resistance and new therapies in ovarian cancer
We study the molecular mechanisms responsible for tumorigenicity and resistance to therapy in ovarian tumors with an impact on worse survival, as well as the parallel search for new personalized and less invasive therapies in ovarian cancer. This research is carried out using in vitro and in vivo models, as well as patient samples. In this context, we analyze the role of certain factors such as:
- DNA repair mechanisms in ovarian cancer.
- The tumor microenvironment in therapy-resistant ovarian cancer.
- Generation of new models of ovarian cancer.
- Identification of new treatments for ovarian cancer
Contact: Sandra Muñoz Galván (smunoz-ibis@us.es)
- Metabolic and signaling pathway alterations in cancer
We study metabolic alterations and alterations in the signaling pathways of cancer cells. Our research covers various methodologies, including bioinformatics as a tool, along with molecular biology, cell biology and microscopy, among others. Our objective is:
- To unravel the underlying mechanisms driving tumorigenesis related to metabolic alterations.
- To identify new therapeutic targets and innovative treatment strategies focusing on metabolic alterations and cancer signaling pathways.
Contact: José Manuel García Heredia (jmgheredia@us.es)
